requiring calibration in 44 cases and surgical revision in 5 cases. Daily activity limitation and tiredness were present respectively in 4% and 17.5%.
INTRODUCTION AND OBJECTIVES: Augmentation cystoplasty is a surgical option for patients with neurogenic bladder disorders. The literature describes preservation of renal function in such patients shortly following surgery but does not explore the long term outcomes. This study examines the long term effect of bladder augmentation on renal function, and predicts which patients are more likely to have deteriorating renal failure over time.
METHODS: 276 patients underwent augmentation cystoplasty between 1981 and 2004, by a single surgeon. A retrospective database was collated with clinical outcomes for these patients over 20-30 years following initial surgery. Results were recorded at 5 year intervals, and renal function was measured as estimated glomerular filtration rate (eGFR).
RESULTS: 169 patients had adequate follow up (70 female:99 male). At the time of augmentation cystoplasty the mean age of the patients was 23.7 years (3.7-73 years). Mean length of follow up was 25 years (10-32 years).
119 had a congenital bladder disorder, with 100 having spina bifida (SB) as the underlying aetiology. The other congenital bladder disorders will be considered as one group and consisted of congenital anatomical anomalies (CAA) mainly exstrophy-related. 50 patients had acquired bladder dysfunction (ABD). At the time of the initial operation the mean age of patients with SB was 18.5 years (4.3-48.7 years); CAA 18.4 years (3.8-43.6 years); and ABD 36.5 years (3.7-73 years). Ileocystoplasty was performed in 134 patients, caecocystoplasty in 27 patients, and colocystoplasty in 8.
Of 169 patients, renal function declined by 22.8ml/min over 30 years. This is in line with the physiological decline of 0.75ml/min/year in a healthy individual. The fall in eGFR in patients with ABD was 34ml/ min, in CAA was 18ml/min and in patients with SB was 5.7ml/min. In those patients aged 0-19 years at time of operation (n[89) the fall in eGFR was 20.5ml/min, whereas those aged 40-59 years (n[25) show a decline of 29.3ml/min. Those having had an ileocystoplasty had an overall decline of 18.5ml/min over 30 years, whereas those with a colocystoplasty had the most significant fall in eGFR of 31ml/min. Of the 169 patients, 3 (1.8%) had a kidney transplant, and 4 (2.4%) had a nephrectomy over the 30 years studied.
CONCLUSIONS: Patients with ABD show a more marked decline in renal function, related to their older age, and reduced renal function at time of surgery. Pre-op renal function, aetiology and age are important factors when considering counselling patients regarding lifetime decline in renal function following augmentation cystoplasty.
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PD33-07 DOES INCORPORATION OF ROBOT-ASSISTED INTRA-CORPOREAL NEOBLADDER IMPACT HEALTH-RELATED QUALITY OF LIFE OUTCOMES? A MATCHED ANALYSIS
Tomoaki Terakawa, Kobe, Japan; Ahmed A. Hussein*, Zaeem Lone, Ahmed S. Elsayed, Naif A. Aldhaam, Zhe Jing, Paul May, Qiang Li, Khurshid A. Guru, Buffalo, NY INTRODUCTION AND OBJECTIVES: Intra-corporeal orthotopic neobladder substitution has been incorporated in clinical practice with changes intechnique to assist with robot-assisted approach. There is lack of sufficient evidence for the equality of patient related results with this novel over the traditional open approach. We aimed to perform a matched comparison between different types of diversion after robot-assisted radical cystectomy (RARC).
METHODS: Retrospective review of patients who underwent RARC in our institution was performed. Patients were divided into 3 groups: intracorporeal neobladder (ICNB), extracorporeal neobladder (ECNB), intracorporeal ileal conduit (ICIC). Propensity score match for patient and disease characteristics was performed. QoL was assessed using the Bladder Cancer Index (BCI) and European Organization for Research and Treatment of Cancer Body Image scale (BIS) questionnaires were utilized to evaluate health-related QoL at 3 time points after RARC: early (3-6 m), intermediate (6-12 m) and late (>12 m). ICNB was compared to ECNB, then another comparison between ICNB and ICIC was performed. Logistic regression model was utilized to evaluate predictors of better QoL for all domains at each time point.
RESULTS: 11 patients in each of the ICNB and ECNB groups and 22 patients ICIC were identified. There was no significant difference in perioperative and pathologic outcomes between all groups. Compared to ECNB, ICNB was not inferior in urinary, bowel, sexual function and body image domains at all time points ( Figure 1A ). On the other hand, urinary function scores in ICIC was significantly better than ICNB (94 vs 54, p[0.006) early after surgery, but this difference decreased with time (92 vs 73, p[0.06 at 6-12 months) and (90 vs 73, p[0.20 at >12 months) ( Figure 1B) . Early after RARC, type of diversion (ileal conduit, mean þ30 points) was associated with better urinary function scores. On intermediate follow up, males demonstrated higher urinary function scores. The effect of these 2 variables diminished after 1 year of follow up.
CONCLUSIONS: Incorporation of ICNB (initial experience and technique evolution) were not associated with changes in QoL after RARC. The difference between ICNB and ICIC diminished at 1 year.
